Mark R. Bray
12Patents
3h-index
16Co-inventors
57Inventor score
Filing activity: Dec 8, 1998 → Apr 23, 2020
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7713915B1 | Cytotoxic heteromeric protein combinatorial libraries | Human Necessities | 14 | Expired |
| US8114870B2 | Method of treating disease states using substituted pyrazole compounds | Chemistry; Metallurgy | 6 | Active |
| US9642856B2 | Treatment for pancreatic cancer | Chemistry; Metallurgy | 5 | Active |
| US12286476B2 | FCMR-binding molecules and uses thereof | Chemistry; Metallurgy | 0 | Active |
| US7563787B2 | Substituted pyrazole compounds | Chemistry; Metallurgy | 0 | Active |
| US9555042B2 | Treatment for pancreatic cancer | General | 0 | Revoked |
| US11766437B2 | Combination therapies for inhibition of TTK protein kinase | Human Necessities | 0 | Active |
| US12325700B2 | Crystal form S4 of the PLK4 inhibitor (1R,2S)-(e)-2-(3-(4-((cis-2,6-dimethylmorpholino)methyl)styryl)-1 h-imidazol-6-yl)-5′-methoxyspiro[cyclopropane-1,3′-indolin]-2′-one fumarate | Chemistry; Metallurgy | 0 | Active |
| US12404327B2 | LILRB3-binding molecules and uses therefor | Chemistry; Metallurgy | 0 | Active |
| US12109215B2 | Combination therapies for inhibition of polo-like kinase 4 | Human Necessities | 0 | Active |
| US10239881B2 | RIPK2 inhibitors and method of treating cancer with same | Human Necessities | 0 | Active |
| US10875863B2 | RIPK2 inhibitors and method of treating cancer with same | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.